Back to Continuing Education

Want to buy for someone else? You can purchase a token at check out.

Overview
Goals and Outcomes
Details
Accreditations
Overview
Overview
The goal of this continuing education module is to help nurses, physicians and therapists understand cystic fibrosis and the latest treatments available.
Goals and Outcomes
Goals and Learning Outcomes
Cystic fibrosis is an autosomal recessive disease that affects approximately 30,000 children and adults in the U.S. It is a chronic, multisystem disorder that significantly reduces life expectancy. Primary manifestations include progressive obstructive lung disease and pancreatic insufficiency, but patients also may experience chronic sinusitis, nasal polyps, malnutrition, distal intestinal obstructive syndrome, diabetes, liver cirrhosis, pancreatitis, gallstones, and infertility. To have cystic fibrosis, a child must inherit two abnormal cystic fibrosis genes, one from each parent. Each time two carriers have a child, there is a 25% chance the baby will have cystic fibrosis. This module provides updated information on the treatment and management of people with cystic fibrosis.

After taking this course, you should be able to:

  • Describe the basic defect that causes cystic fibrosis and how the disease affects different organ systems.
  • Identify three therapies for the management of pulmonary and gastrointestinal disease in patients with cystic fibrosis.
  • Explain teaching and support responsibilities of clinical personnel for patients with CF and their families.
  • Discuss the status of research into new treatments and potential cures for cystic fibrosis.
  • Describe the basic defect that causes cystic fibrosis and how it affects different organ systems
  • Identify three therapies for the management of pulmonary and GI disease in patients with cystic fibrosis
  • Explain teaching and support responsibilities
  • Discuss research and the future of cystic fibrosis

Course Termination Date: 05/06/23

Content Expiration Date: 05/31/23

Course Originally Released On: 05/01/19
Details
Course Details

Course Originally Released on : 5/1/2019

REL-ACU-0-CE534

Course Author

Deborah S. Boroughs

MSN, RN

Joan A. Dougherty

RN, BSN, CPN, CSN

Carrie Furberg

BSN, RN, CRN

Accreditations
Accreditations

NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Accreditations imageAccreditations image

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

CEBroker
Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Examiners For Registered Professional Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.